News: The Latest
Press Releases
Bicara Therapeutics Expands Board of Directors with Appointments of Kate Haviland and Scott Robertson
Bicara Therapeutics Expands Management Team with the Appointment of David Raben, M.D., as Chief Medical Officer
Contact Information
GENERAL
[email protected]
617-468-4219
BUSINESS DEVELOPMENT
MEDIA
Dan Budwick
1AB
[email protected]
INVESTORS
Hannah Deresiewicz
Stern Investor Relations, Inc.
[email protected]
Presentations & Publications
Poster Presentation: Updated dose expansion results of a Phase 1/1b study of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma
2024 Multidisciplinary Head and Neck Cancers Symposium
March 2024
Poster Presentation: Combination with BCA101 improves the efficacy of KRAS-G12C inhibitor and overcomes G12C inhibitor-induced resistance in lung and colon cancer cells
Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
November 2023
Poster Presentation: Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma
European Society for Medical Oncology
October 2023
Webinar: ASCO 2023 Update: BCA101 With Pembrolizumab Dose Expansion Results in Patients With R/M HNSCC
Presented by Bicara Therapeutics
June 2023
Publication: BCA101, a novel tumor-targeted bifunctional fusion antibody simultaneously inhibiting EGFR and TGF-β signaling with potential for durable tumor growth inhibition
Cancer Research
April 2023
Poster Presentation: BCA101, a novel tumor-targeted bifunctional fusion antibody simultaneously inhibiting EGFR and TGF-β signaling with potential for durable tumor growth inhibition
American Association for Cancer Research 2023 Annual Meeting
April 2023
Poster Presentation: Preliminary immune correlatives from BCA101 trial show favorable modulation of tumor immune microenvironment
American Association for Cancer Research 2023 Annual Meeting
April 2023
Poster Presentation: An improved trispecific antibody (TsAb) platform for optimally engaging T cells for the treatment of solid tumor malignancies
American Association for Cancer Research 2023 Annual Meeting
April 2023
Poster Presentation: A novel bispecific BCA356 targeting tumor antigen CAIX conjugated to an attenuated IL-12 demonstrates pre-clinical efficacy with potential for limited systemic toxicity
Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
November 2022
Webinar: Clinical Update on BCA101: Overview and Discussion of Newly Presented Data
Presented by Bicara Therapeutics
September 2022
Poster Presentation: A Phase I trial of the bifunctional EGFR/TGFβ fusion protein BCA101 alone and in combination with pembrolizumab in patients with advanced solid cancers
American Society of Clinical Oncology
June 2022
Poster Presentation: Development of BCA101, a bifunctional antibody capable of simultaneously disabling EGFR and TGF-β Signaling, as a novel single-agent immunotherapy
Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting
November 2021
Digital Presentation: First-in-human Phase I study of the bifunctional EGFR/TGFβ fusion protein BCA101 in patients with EGFR-driven advanced solid cancers
American Society of Clinical Oncology
June 2021